199 related articles for article (PubMed ID: 37750953)
21. Brolucizumab for recalcitrant macular neovascularization in age-related macular degeneration with pigment epithelial detachment.
Chronopoulos A; Huynh E; Ashurov A; Schutz JS; Jonas JB; Hattenbach LO
Eur J Ophthalmol; 2024 Mar; 34(2):487-496. PubMed ID: 37461836
[TBL] [Abstract][Full Text] [Related]
22. Baseline characteristics associated with the incidence of intraocular inflammation after the intravitreous injection of brolucizumab.
Hoshi K; Kunikata H; Aizawa N; Yasuda M; Okabe T; Takizawa H; Abe T; Nakazawa T
Int Ophthalmol; 2023 Dec; 43(12):4701-4709. PubMed ID: 38044420
[TBL] [Abstract][Full Text] [Related]
23. Real-World Experience Using Intravitreal Brolucizumab Alone or in Combination with Aflibercept in the Management of Neovascular Age-Related Macular Degeneration.
Mehta N; Fong RD; Wilson M; Moussa K; Emami-Naeini P; Moshiri A; Yiu G; Park SS
Clin Ophthalmol; 2023; 17():657-665. PubMed ID: 36880020
[TBL] [Abstract][Full Text] [Related]
24. Clinical Outcomes of Faricimab in Patients with Previously Treated Neovascular Age-Related Macular Degeneration.
Pandit SA; Momenaei B; Wakabayashi T; Mansour HA; Vemula S; Durrani AF; Pashaee B; Kazan AS; Ho AC; Klufas M; Regillo C; Yonekawa Y; Hsu J; Kuriyan A; Chiang A
Ophthalmol Retina; 2024 Apr; 8(4):360-366. PubMed ID: 37913992
[TBL] [Abstract][Full Text] [Related]
25. Early Experience With Brolucizumab Treatment of Neovascular Age-Related Macular Degeneration.
Enríquez AB; Baumal CR; Crane AM; Witkin AJ; Lally DR; Liang MC; Enríquez JR; Eichenbaum DA
JAMA Ophthalmol; 2021 Apr; 139(4):441-448. PubMed ID: 33630045
[TBL] [Abstract][Full Text] [Related]
26. Using optical coherence tomography angiography in assessment of the anti-vascular endothelial growth factor effect for pathological vascular tissue in age-related macular degeneration and polypoidal choroidal vasculopathy.
Shen YS; Cheng CK
Eur J Ophthalmol; 2021 May; 31(3):1267-1280. PubMed ID: 32228025
[TBL] [Abstract][Full Text] [Related]
27. MERLIN: Phase 3a, Multicenter, Randomized, Double-Masked Trial of Brolucizumab in Participants with Neovascular Age-Related Macular Degeneration and Persistent Retinal Fluid.
Khanani AM; Brown DM; Jaffe GJ; Wykoff CC; Adiguzel E; Wong R; Meng X; Heier JS;
Ophthalmology; 2022 Sep; 129(9):974-985. PubMed ID: 35537533
[TBL] [Abstract][Full Text] [Related]
28. Long-term choroidal thickness changes based on the subtype of macular neovascularization in neovascular age-related macular degeneration (5-year follow-up).
Abdin AD; Hanifa O; Aljundi W; Munteanu C; Seitz B; Suffo S
Graefes Arch Clin Exp Ophthalmol; 2024 Feb; 262(2):457-468. PubMed ID: 37864635
[TBL] [Abstract][Full Text] [Related]
29. HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration.
Dugel PU; Koh A; Ogura Y; Jaffe GJ; Schmidt-Erfurth U; Brown DM; Gomes AV; Warburton J; Weichselberger A; Holz FG;
Ophthalmology; 2020 Jan; 127(1):72-84. PubMed ID: 30986442
[TBL] [Abstract][Full Text] [Related]
30. Short-Term Safety and Efficacy of Intravitreal Brolucizumab Injections for Neovascular Age-Related Macular Degeneration: A Multicenter Retrospective Real-World Study.
Kim DJ; Jin KW; Han JM; Lee SH; Park YS; Lee JY; Lee EK; Lee JS; Kim ST; Shin MH; Lee CS; Jung HH; Jang JY; Kim M; Kim YH; Kim JH; Park KH; Park SJ; Joo K; Ji YS; Sagong M; Woo SJ
Ophthalmologica; 2023; 246(3-4):192-202. PubMed ID: 36720210
[TBL] [Abstract][Full Text] [Related]
31. Brolucizumab Intravitreal Injections for Wet Age-Related Macular Degeneration: Real-Life Study on a Cohort of Italian Patients.
Gesualdo C; Rossi S; Iodice CM; Guarino F; Petrella M; D'Agostino FA; Perrotta R; Simonelli F
Medicina (Kaunas); 2023 Jun; 59(6):. PubMed ID: 37374314
[No Abstract] [Full Text] [Related]
32. Efficacy and safety of brolucizumab in age-related macular degeneration: A systematic review of real-world studies.
Baumal CR; Sørensen TL; Karcher H; Freitas RL; Becher A; Balez S; Clemens A; Singer M; Kodjikian L
Acta Ophthalmol; 2023 Mar; 101(2):123-139. PubMed ID: 36117281
[TBL] [Abstract][Full Text] [Related]
33. Risk of Inflammation, Retinal Vasculitis, and Retinal Occlusion-Related Events with Brolucizumab: Post Hoc Review of HAWK and HARRIER.
Monés J; Srivastava SK; Jaffe GJ; Tadayoni R; Albini TA; Kaiser PK; Holz FG; Korobelnik JF; Kim IK; Pruente C; Murray TG; Heier JS
Ophthalmology; 2021 Jul; 128(7):1050-1059. PubMed ID: 33207259
[TBL] [Abstract][Full Text] [Related]
34. RETINAL PIGMENT EPITHELIAL TEAR AFTER INTRAVITREAL RANIBIZUMAB TREATMENT FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.
Cho HJ; Kim HS; Yoo SG; Han JI; Lew YJ; Cho SW; Lee TG; Kim JW
Retina; 2016 Oct; 36(10):1851-9. PubMed ID: 27074658
[TBL] [Abstract][Full Text] [Related]
35. Brolucizumab in recalcitrant neovascular age-related macular degeneration-real-world data in Chinese population.
Weng CC; Chi SC; Lin TC; Huang YM; Chou YB; Hwang DK; Chen SJ
PLoS One; 2024; 19(4):e0301096. PubMed ID: 38564612
[TBL] [Abstract][Full Text] [Related]
36. Changes in the uninjected contralateral eye after intravitreal brolucizumab for exudative age-related macular degeneration.
Mora P; Bellucci C; Radice LM; Manzotti F; Gandolfi S
Eur J Ophthalmol; 2024 Jan; 34(1):NP104-NP107. PubMed ID: 37424299
[TBL] [Abstract][Full Text] [Related]
37. Real-world experience with brolucizumab in neovascular age-related macular degeneration over 2 years: the REBA extension study.
Bilgic A; Kodjikian L; de Ribot FM; Spitzer MS; Vasavada V; Gonzalez-Cortes JH; Sudhalkar A; Chakraborty S; Mathis T
Graefes Arch Clin Exp Ophthalmol; 2024 Apr; 262(4):1161-1167. PubMed ID: 38063874
[TBL] [Abstract][Full Text] [Related]
38. Intravitreal anti-vascular endothelial growth factor monotherapy in age-related macular degeneration with submacular hemorrhage.
Maruyama-Inoue M; Kitajima Y; Yanagi Y; Inoue T; Kadonosono K
Sci Rep; 2023 Apr; 13(1):5688. PubMed ID: 37029159
[TBL] [Abstract][Full Text] [Related]
39. Prognostic factors after aflibercept therapy for typical age-related macular degeneration and polypoidal choroidal vasculopathy.
Ogasawara M; Koizumi H; Yamamoto A; Itagaki K; Saito M; Maruko I; Okada AA; Iida T; Sekiryu T
Jpn J Ophthalmol; 2018 Sep; 62(5):584-591. PubMed ID: 29974277
[TBL] [Abstract][Full Text] [Related]
40. Investigation of satisfaction with short-term outcomes after switching to faricimab to treat neovascular age-related macular degeneration.
Hikichi T
Jpn J Ophthalmol; 2023 Nov; 67(6):652-656. PubMed ID: 37861941
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
